Could lead to falsely high or low results, especially troponin assays.
Approved for ages 65 and older.
First and currently only rifabutin-based H. pylori therapy approved.
Delayed-release oral capsules for various forms of the disease.
Commercial launch suspended due to manufacturer liquidity.
New formulation improves safety for patients.
Previously approved for IV infusion.
Fourth indication expansion for the 2009 drug.
Reduces risk for heart failure and cardiovascular disease hospitalizations.
Drug able to treat 18,000 people will cost over $300k per year.